Follow-up: The lowest dose that does anything: is that a real question? posts 31–60

A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.

Nothing to add on the substance. Thank you for taking the question at face value.

Worth separating two things that post #45 runs together.

Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.

Where I would look next, rather than where I would stop.

Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.

It is the kind of thing that is obvious once and never again.

Post #45 describes the usual case. This is about the unusual one.

When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.

The number is defensible. The precision I gave it is not.

The failure mode on lowest dose is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.

Acknowledging rather than arguing. The reasoning holds as far as I can follow it.

Post #50 put the caveat in the right place and I want to underline it.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

Worth checking against a second source before it gets quoted onward.

Post #52 answers the question as asked. The question underneath it is different.

If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.

Anyone with a larger sample, please post it.

What I can speak to on lowest dose is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.

Reading back through, this was answered upthread and I missed it. My fault.